# BMEA — Biomea Fusion Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** BMEA  
**Sources:** 18  
**Published:** 2026-10-12  
**Canonical:** https://app.k3vl4r.com/research/deep-research-bmea-biomea-fusion-inc-catalysts-narrative-risks-7203

---

# Biomea Fusion, Inc. (Nasdaq: BMEA) — As of 2026-10-12

## Background / positioning
Biomea Fusion is a clinical-stage diabetes and obesity medicines company based in San Carlos, California, focused on oral small-molecule therapies, notably **icovamenib** (formerly BMF-219, an oral covalent menin inhibitor) and **BMF-650** for obesity [[2]](https://finance.yahoo.com/markets/stocks/articles/biomea-fusion-announces-proposed-public-200500609.html), [[6]](https://www.marketscreener.com/news/biomea-fusion-inc-nasdaqgs-bmea-dropped-from-s-p-global-bmi-index-ce785adbd988ff2c), [[13]](https://www.marketbeat.com/stocks/NASDAQ/BMEA/). It is a micro-cap with a market cap of roughly $102.9M, no revenue, and a stock that has traded between ~$0.87 and $2.24 over the past year [[10]](https://tickernerd.com/stock/bmea-forecast/), [[13]](https://www.marketbeat.com/stocks/NASDAQ/BMEA/), [[15]](https://finance.yahoo.com/quote/BMEA/).

## Recent catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-bmea-biomea-fusion-inc-catalysts-narrative-risks-7203 (free to sign up)._
